You miss 100% of the shots you take (on WallStreetBets)
GENE logo

GENE

Genetic Tech Spn Ads

Price Data Unavailable

About Genetic Tech Spn Ads

View all WallStreetBets trending stocks

Premarket Buzz
0
Comments today 12am to 9:30am EST


Comment Volume (7 days)
5
Total Comments on WallstreetBets

6
Total Comments on 4chan's biz

View all WallStreetBets trending stocks

Recent Comments

Why isn't gene editing a bigger deal? It's actual real life sci fi instead of some crapshoot like quantum computing. Maybe the only thing that matters nowadays is computers. Everything is computer!!
Futes gene af 🧬
Forget AI. It's gene editing time. IRL Gattaca.
Gene Editing to the Moon CRSP NTLA BEAM
There are a number of different talks, which do include patient safety data, here is some directly related to elevidys: From Sarepta’s press release: • Sarepta will present data from its neuromuscular portfolio at WMS 2025, including several studies in the delandistrogene moxeparvovec (Elevidys) clinical development program, as well as a real-world evidence study of pulmonary function in advanced patients.  • The release also gives two abstracts / session items they intend to present: 1. “676P: One-year motor function outcomes following treatment with delandistrogene moxeparvovec in young boys with Duchenne muscular dystrophy: a single center experience” — Oct 8, 2025, 8:30-9:30 a.m. EDT  2. “732LBP: Preliminary analysis of safety, tolerability, and efficacy of a prophylactic sirolimus protocol for patients receiving delandistrogene moxeparvovec-rokl gene therapy (late-breaker)” — Oct 10, 2025, 9:45-10:45 a.m. EDT[https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-present-new-data-its-neuromuscular-0](https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-present-new-data-its-neuromuscular-0)
View All

Next stock GENY

Previous stock GENC